{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-258534","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2022-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.889820+00:00","generated_at":"2026-06-23T05:11:15.301740+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AN2 Therapeutics updates epetraborole development; Phase 1 Japan study supports 500 mg dose; EU orphan designation","bullets":["Phase 1 study in Japanese volunteers (EBO-103) showed no adverse events, supports once-daily 500 mg dose for Phase 2/3.","Epetraborole exposures similar across ADH genotypes and consistent with prior Phase 1 study in non-Japanese subjects.","EU Commission granted orphan medicinal product designation for epetraborole in NTM lung disease.","Company plans to initially focus clinical development for treatment-refractory MAC lung disease on Japan and the U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-258534","json":"https://secwatch.observer/filing/0001193125-22-258534.json","markdown":"https://secwatch.observer/filing/0001193125-22-258534.md","text":"https://secwatch.observer/filing/0001193125-22-258534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522258534/0001193125-22-258534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522258534/d383473d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:11:15.301740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}